Literature DB >> 2642504

Secretion of novel and homologous neutrophil-activating peptides by LPS-stimulated human endothelial cells.

J M Schröder1, E Christophers.   

Abstract

Human umbilical vein endothelial cells in culture produce two chemotactic polypeptides when stimulated with LPS. The chemotactic factors could be purified to apparent homogeneity by HPLC techniques and were identified as 7.5-kDa and 15-kDa polypeptides by SDS-PAGE under nonreducing conditions. Both factors are potent chemotaxins for human neutrophils demonstrating half-maximal chemotaxis at 2 ng/ml and g ng/ml, respectively. In addition both peptides elicited release of azurophilic granule constituents when neutrophils were pretreated with cytochalasin B. Cross-desensitization experiments by using human neutrophils revealed cross-reactivities between both chemotaxins, not, however, with C5a or FMLP, indicating that both endothelial cell-derived neutrophil activating peptides (ENAP) are homologous. In addition, the 7.5-kDa factor (beta-ENAP) proved to be the quantitatively dominating and more potent chemotaxin as compared to the 15 kDa factor (alpha-ENAP). beta-ENAP shows biochemical and biologic similarities to monocyte- and lymphocyte-derived neutrophil-activating peptides MONAP and LYNAP, which recently were purified and sequenced.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642504

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  The role of CD18 in IL-8 induced dermal and synovial inflammation.

Authors:  M J Forrest; G J Eiermann; R Meurer; L A Walakovits; D E MacIntyre
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  TNF-α induces vectorial secretion of IL-8 in Caco-2 cells.

Authors:  Dennis I Sonnier; Stephanie R Bailey; Rebecca M Schuster; Alex B Lentsch; Timothy A Pritts
Journal:  J Gastrointest Surg       Date:  2010-09-09       Impact factor: 3.452

3.  Production of interleukin 8 by cultured synovial cells in response to interleukin 1 and tumor necrosis factor.

Authors:  K Hirota; T Akahoshi; H Endo; H Kondo; S Kashiwazaki
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

Review 4.  Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

Authors:  M Baggiolini; A Walz; S L Kunkel
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

5.  Roles of ERK and NF-kappaB in Interleukin-8 Expression in Response to Heat Shock Protein 22 in Vascular Smooth Muscle Cells.

Authors:  Seung-Hun Kang; Ji-Hyuk Lee; Kyung-Ha Choi; Byung-Yong Rhim; Koanhoi Kim
Journal:  Korean J Physiol Pharmacol       Date:  2008-08-31       Impact factor: 2.016

6.  Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis.

Authors:  Y Raab; B Gerdin; S Ahlstedt; R Hällgren
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

7.  Inhibition by new glucocorticoid antedrugs [16α, 17α-d] isoxazoline and [16α, 17α-d]-3'-hydroxy-iminoformyl isoxazoline derivatives of chemotaxis and CCL26, CCL11, IL-8, and RANTES secretion.

Authors:  Younes J Errahali; Leeshawn D Thomas; Thomas C S Keller; Henry J Lee
Journal:  J Interferon Cytokine Res       Date:  2013-05-16       Impact factor: 2.607

8.  Cardioprotective and endothelial protective effects of [Ala-IL8]77 in a rabbit model of myocardial ischaemia and reperfusion.

Authors:  A M Lefer; G Johnson; X L Ma; P S Tsao; G R Thomas
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

9.  Elevated interleukin-8 levels in the urine of patients with urinary tract infections.

Authors:  Y C Ko; N Mukaida; S Ishiyama; A Tokue; T Kawai; K Matsushima; T Kasahara
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

10.  Effects of interleukin-8 on nonspecific resistance to infection in neutropenic and normal mice.

Authors:  M T Vogels; I J Lindley; J H Curfs; W M Eling; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.